STAMP (tissue typer) online meeting 2nd of December 2020

Participants: Bjarne Møller, Mats Bengtsson, Jouni Lauronen, Christian Naper & Ilse Weinreich

Purpose: To identify any potential obstacles in the current STAMP approval process to make the time to acceptance shorter. This relates in particular to communication between the committee and the individual center that enters the patients.

1. Suggestions for improvements

a. YASWA

- i. New QC that discloses antibodies against own antigens
- ii. Evaluation list should only contain patients active on the waiting list
- iii. Investigate how to handle DPB1 better
- iv. Add extra code in the STAMP log that can be selected by the committee when more information is needed.
- v. Investigate solution for removing the patients from the evaluation list when the committee has selected 'Disapproved' or 'More information needed'.

b. Committee

- i. It has been approved that Tartu is allowed to have a member in the committee. Ilse will make contact.
- ii. Aim to have first evaluation of each patient done within 4 weeks

c. Centers

- i. In the evaluation process when a patient record is updated by a lab. an entry must be made in the STAMP log with details about the update
- ii. It is recommended that each center only have two patients on the list for evaluation at the same time
- iii. Remember to inactivate antibodies that are not clinical relevant
- iv. It is recommend not to enter patients that only have weak antibodies
- 2. <u>Update of STAMP guidelines (STAMP/LAMP (Scandiatransplant and Local acceptable mismatch program Manual)</u> version 8.1 revised December 1st, 2017)
 - a. Guidelines will be revised, circulated in the following order: Jouni -> Mats -> Christian ->
 Bjarne -> Ilse
 - b. Updated guidelines will be sent to all centers for feedback. Does it cover the information that is needed?

3. Status on STAMP publication

- a. Currently 275 patients have been transplanted through STAMP
- b. April 1st 2020 all alleles were included in the program
- c. First publication will focus on HLA (TS and alleles)
- d. At the time where all new alleles where introduced until today 187 patients have been/are on STAMP. On these patients we have complete antibody and acceptable mismatch profiles.
- e. Pernille and Ilse will take the lead on the initial writing

4. Online meetings

The group would like to have regular meetings to discuss problematic cases, process, policies etc. Next meeting will be 3rd of February 2021 10.00-12.00 CET